5.6% annual growth forecast for multiple myeloma drug market to 2020
Driven by further penetration of Celgene’s Revlimid (lenalidomide) into the first-line setting and the launch of premium-priced emerging therapies, the multiple myeloma drug market will experience robust 5.6% annual growth from 2010 to 2020 in the leading markets of the USA, France, Germany, Italy, Spain, the UK and Japan, according to a new report from health care advisory firm Decision Resources.
Three agents currently dominate sales in the myeloma market: Celgene’s Revlimid, Takeda/Janssen-Cilag/Janssen’s Velcade (bortezomib), and Celgene’s Thalidomide/Thalomid and Fujimoto Seiyaku’s Thaled (thalidomide). In a report issued last year, Decision Resources forecast that the multiple myeloma market would rise from a value of $2.1 billion in 2008 to $5.3 billion in 2018.
Revlimid to eclipse Velcade
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze